These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21317177)

  • 1. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study.
    Vermeire S; Ghosh S; Panes J; Dahlerup JF; Luegering A; Sirotiakova J; Strauch U; Burgess G; Spanton J; Martin SW; Niezychowski W
    Gut; 2011 Aug; 60(8):1068-75. PubMed ID: 21317177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
    Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Dubé R; Cohen A; Steinhart AH; Landau S; Aguzzi RA; Fox IH; Vandervoort MK
    N Engl J Med; 2005 Jun; 352(24):2499-507. PubMed ID: 15958805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
    Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
    Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
    Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells.
    Picarella D; Hurlbut P; Rottman J; Shi X; Butcher E; Ringler DJ
    J Immunol; 1997 Mar; 158(5):2099-106. PubMed ID: 9036954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1.
    Kato S; Hokari R; Matsuzaki K; Iwai A; Kawaguchi A; Nagao S; Miyahara T; Itoh K; Ishii H; Miura S
    J Pharmacol Exp Ther; 2000 Oct; 295(1):183-9. PubMed ID: 10991977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan.
    Hibi T; Sameshima Y; Sekiguchi Y; Hisatome Y; Maruyama F; Moriwaki K; Shima C; Saniabadi AR; Matsumoto T
    Dig Liver Dis; 2009 Aug; 41(8):570-7. PubMed ID: 19211314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.
    Sands BE; Sandborn WJ; Feagan B; Löfberg R; Hibi T; Wang T; Gustofson LM; Wong CJ; Vandervoort MK; Hanauer S;
    Gastroenterology; 2008 Aug; 135(2):400-9. PubMed ID: 18602921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab.
    Wyant T; Estevam J; Yang L; Rosario M
    Cytometry B Clin Cytom; 2016 Mar; 90(2):168-76. PubMed ID: 25908521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients.
    Tanaka T; Okanobu H; Yoshimi S; Murakami E; Kogame A; Imagawa H; Numata Y; Kuga Y; Moriya T; Ohya T; Kajiyama G
    Dig Liver Dis; 2008 Sep; 40(9):731-6. PubMed ID: 18387860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis.
    Levine DS; Fischer SH; Christie DL; Haggitt RC; Ochs HD
    Am J Gastroenterol; 1992 Jan; 87(1):91-100. PubMed ID: 1728132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
    Sandborn WJ; Bhandari BR; Fogel R; Onken J; Yen E; Zhao X; Jiang Z; Ge D; Xin Y; Ye Z; French D; Silverman JA; Kanwar B; Subramanian GM; McHutchison JG; Lee SD; Shackelton LM; Pai RK; Levesque BG; Feagan BG
    Aliment Pharmacol Ther; 2016 Jul; 44(2):157-69. PubMed ID: 27218676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.